<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518670</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-Co-001</org_study_id>
    <nct_id>NCT04518670</nct_id>
  </id_info>
  <brief_title>Success in Comaneci-assist Coils Embolization Surveillance Study (SUCCESS)</brief_title>
  <official_title>Success in Comaneci-assist Coils Embolization Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rapid Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Comaneci Embolization Assist Device is indicated for use in the neurovasculature as a&#xD;
      temporary endovascular device used to assist in the coil embolization of wide-necked&#xD;
      intracranial aneurysms with a neck width ≤ 10 mm. A wide-necked intracranial aneurysm (IA)&#xD;
      defines the neck width as ≥ 4 mm or a dome-to-neck ratio &lt; 2.&#xD;
&#xD;
      The objective of the Postmarket Surveillance Plan is to assess safety and performance as used&#xD;
      in postmarket clinical practice in the U.S.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Periprocedural events</measure>
    <time_frame>24 Hours post procedure</time_frame>
    <description>Rates of all adverse events occurring within 24 hours post-procedure and hospital discharge status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>All adverse events at discharge and up to 30 days post procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional status</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Functional status at discharge and 30 days assessed using the modified Rankin Scale (mRS).&#xD;
using the modified Rankin Scale (mRS). This scale runs from 0-6, from no symptoms to death as follows:&#xD;
0 - No symptoms&#xD;
1 - No significant disability. Able to carry out all usual activities, despite some symptoms.&#xD;
2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
3 - Moderate disability. Requires some help, but able to walk unassisted.&#xD;
4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.&#xD;
6 - Dead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful intracranial aneurysm occlusion</measure>
    <time_frame>end of procedure</time_frame>
    <description>Successful intracranial aneurysm occlusion (measured by Raymond Roy classification I or II) at the end of procedure, using digital subtraction angiography (DSA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful intracranial aneurysm (IA) occlusion</measure>
    <time_frame>6 Months Post procedure</time_frame>
    <description>Successful intracranial aneurysm (IA) occlusion, that is a stable IA occlusion, measured by Raymond Roy classification I or II taken at 6 months (± 21d) post procedure without the need for re-treatment of the target IA, using DSA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Good clinical outcome</measure>
    <time_frame>6 Months Post procedure</time_frame>
    <description>Good clinical outcome- mRS shift @ 6 months (change @ 6 months from pre procedure) and tetrachotomized (0,1, 2, 3-6) mRS analysis</description>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comaneci Embolization Assist Device</intervention_name>
    <description>assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Postmarket Sureveillance Study will include male or female patients with wide-necked&#xD;
        ruptured and/or unruptured intracranial aneurysms that may require adjunctive assistance&#xD;
        with coil embolization during the surgical procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has a documented intracranial ruptured or unruptured aneurysm, suitable for&#xD;
             embolization by coils.&#xD;
&#xD;
          2. Patient is considered for treatment with coil embolization assisted by the Comaneci&#xD;
             Device for wide-necked intracranial aneurysms with neck width ≤ 10 mm. A wide-necked&#xD;
             intracranial aneurysm is defined by the neck width as ≥ 4 mm or a dome-to-neck ratio &lt;&#xD;
             2.&#xD;
&#xD;
          3. A signed informed consent by the patient or legally authorized representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patient with known hypersensitivity to nickel-titanium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanel Ricardo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baptist Neurological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walid Haddad, Dr.</last_name>
    <phone>518-545-5250</phone>
    <email>walid@rapid-medical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>‪Neta Maymon‬, MA</last_name>
    <phone>+972545924105</phone>
    <email>neta@rapid-medical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Los Robles</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasia Vechera</last_name>
      <phone>818-388-3544</phone>
      <email>anastasia.vechera@nsbf.us</email>
    </contact>
    <investigator>
      <last_name>Muhammad Asif Taqi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Research Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanaya Lewis, CRC</last_name>
      <phone>904-202-7089</phone>
      <email>Lanaya.lewis@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Hanel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rapid Medical</keyword>
  <keyword>aneurysm</keyword>
  <keyword>Comaneci</keyword>
  <keyword>Neurovascular intervention</keyword>
  <keyword>Brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

